LogicBio Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Updates
August 10, 2020 06:30 ET | LogicBio Therapeutics
LEXINGTON, Mass., Aug. 10, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio or the Company), a company dedicated to extending the reach of genetic medicine with...
AAV Gene Therapy Pioneer Jude Samulski Develops Proprietary Regulated Gene Editing System
June 23, 2020 09:18 ET | Asklepios BioPharmaceutical, Inc.
RESEARCH TRIANGLE PARK, N.C. , June 23, 2020 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical, Inc. (AskBio), a leading, clinical-stage adeno-associated virus (AAV) gene therapy company, today...
LogicBio Therapeutics to Present New Data on GeneRide™ Platform and Next Generation Capsid Development Program at the American Society of Gene & Cell Therapy 2020 Annual Meeting
May 11, 2020 16:10 ET | LogicBio Therapeutics
LEXINGTON, Mass., May 11, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio or the Company), a genome editing company focused on developing medicines to durably treat rare...
GLOBE excision-logo-2019-mark-1c (1).png
Excision BioTherapeutics Announces Data Presentation at CROI from IND-Enabling Non-Human Primate studies of EBT-001, supporting a CRISPR Gene Editing Technology for HIV Elimination
March 11, 2020 15:27 ET | Excision BioTherapeutics
OAKLAND, Calif., March 11, 2020 (GLOBE NEWSWIRE) -- Excision BioTherapeutics, a private biotechnology company focused on applying CRISPR gene editing to curing viral infectious diseases, today...
Precision BioSciences to Report Fiscal Year and Fourth Quarter 2019 Financial Results and Present at Upcoming Investor Conferences
February 21, 2020 07:00 ET | Precision Biosciences
DURHAM, N.C., Feb. 21, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a life sciences company dedicated to improving life through the application of its pioneering, proprietary...
Napigen logo-full.jpg
NAPIGEN Publication Provides Proof of Concept of its Technology for Editing Cytoplasmic Genome (Mitochondrial and Chloroplast Genome)
January 28, 2020 08:15 ET | Napigen, Inc.
WILMINGTON, Del., Jan. 28, 2020 (GLOBE NEWSWIRE) -- NAPIGEN, a company developing proprietary technology to edit mitochondrial and chloroplast genomes, said it demonstrated for the first time the...
LogicBio Therapeutics Announces Submission of Investigational New Drug Application (IND) for LB-001 for Methylmalonic Acidemia (MMA) and Highlights Key Corporate Milestones
January 10, 2020 07:05 ET | LogicBio Therapeutics
– Filed IND for lead GeneRide™ candidate LB-001 in pediatric MMA patients –– Phase 1/2 trial initiation planned for H1 2020, with preliminary data in H2 2020 –– Established research collaboration with...
LogicBio Therapeutics Announces Collaboration with Takeda to Develop New Genome Editing Candidate LB-301 for the Treatment of Crigler-Najjar Syndrome
January 10, 2020 07:00 ET | LogicBio Therapeutics
– LB-301 is a recombinant AAV vector with a UGT1A1 gene leveraging GeneRide™ genome editing platform for the treatment of Crigler-Najjar syndrome – – The collaboration agreement grants Takeda an...
LogicBio Therapeutics Extends Sponsored Research Agreement with Oregon Health & Science University to Explore Translation of Pharmaceutically-Driven Selective Advantage for Future GeneRide™ Candidates 
December 17, 2019 08:00 ET | LogicBio Therapeutics
CAMBRIDGE, Mass., Dec. 17, 2019 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric...
GLOBE excision-logo-2019-mark-1c (1).png
CRISPR-focused Excision BioTherapeutics Strengthens Board of Directors Appointing Veteran Pharmaceutical Executive Bill Carson, M.D.
December 03, 2019 12:30 ET | Excision BioTherapeutics
Oakland, CA, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Excision BioTherapeutics, Inc., a biotechnology company developing CRISPR-based therapies to cure viral infectious diseases, today announced that...